Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: Evaluation of the effect of leukocyte inclusion

Journal of Biomedical Materials Research - Part A

Volumn 103, Issue 3, 2015, Pages 1011-1020

  Anitua, E ^a   Zalduendo, M M ^a   Prado, R ^a   Alkhraisat, M H ^a   Orive, G ^a  

^a Foundation Eduardo Anitua   (Spain)

Author keywords

Fibrin scaffold; Growth factors; Inflammation; Leukocytes; Platelet rich plasma

Indexed keywords

KINETICS; PLASMA (HUMAN); PLATELETS; TISSUE REGENERATION;

FIBRIN SCAFFOLD; GROWTH FACTOR; INFLAMMATION; LEUKOCYTES; PLATELET RICH PLASMA;

SCAFFOLDS (BIOLOGY);

FIBRIN; INTERLEUKIN 16; INTERLEUKIN 1BETA; MORPHOGEN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AB; VASCULOTROPIN; CYTOKINE; EPIDERMAL GROWTH FACTOR; HYDROGEL; INSULIN; PLATELET-DERIVED GROWTH FACTOR AB; SCATTER FACTOR; SIGNAL PEPTIDE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A;

ADHERENT CELL; ARTICLE; BLOOD; CELL CULTURE; CYTOKINE RELEASE; ERYTHROCYTE; GIANT CELL; HUMAN; HUMAN CELL; HYDROGEL; KINETICS; LEUKOCYTE; NORMAL HUMAN; PLASMA RICH GROWTH FACTOR ENDORET FIBRIN SCAFFOLD; SCANNING ELECTRON MICROSCOPY; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TISSUE SCAFFOLD; CELL ADHESION; CHEMISTRY; CYTOLOGY; INFLAMMATION; METABOLISM; OPTICS; PROCEDURES; TISSUE ENGINEERING;

CELL ADHESION; CYTOKINES; EPIDERMAL GROWTH FACTOR; FIBRIN; HEPATOCYTE GROWTH FACTOR; HUMANS; HYDROGELS; INFLAMMATION; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-16; INTERLEUKIN-1BETA; LEUKOCYTES; OPTICS AND PHOTONICS; PLATELET-DERIVED GROWTH FACTOR; PLATELET-RICH PLASMA; TISSUE ENGINEERING; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922990205     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35244     Document Type: Article

References (55)

1. Anitua E, Zalduendo MM, Alkhraisat M, Orive G. Release kinetics of platelet-derived and plasma-derived growth factors from auto-logous plasma rich in growth factors. Ann Anat 2013; 195:461-466.
2. Anitua E, Prado R, Azkargorta M., Rodriguez-Suarez E, Iloro I, Casado-Vela J, Elortza F., Orive G. High-throughput proteomic characterization of plasma rich in growth factors (PRGF-Endoret)-derived fibrin clot interactome. J Tissue Eng Regen Med 2013. doi:10.1002/term.1721.
3. Del Buono A, Papalia R, Denaro V., Maccauro G, Maffulli N. Platelet rich plasma and tendinopathy: State of the art. Int J Immuno-pathol Pharmacol 2011; 24:79-83.
4. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006; 34:1774-1778.
5. Sanchez M, Anitua E, Azofra J., Andia I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med 2007; 35:245-251.
6. Sanchez M, Anitua E, Azofra J., Prado R, Muruzabal F, Andia I. Lig-amentization of tendon grafts treated with an endogenous preparation rich in growth factors: Gross morphology and histology. Arthroscopy 2010; 26:470-480.
7. Sanchez M, Fiz N, Azofra J., Usabiaga J, Aduriz Recalde E, Garcia Gutierrez A, Albillos J, Garate R, Aguirre JJ, Padilla S, Orive G, Anitua E. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy 2012; 28:1070-1078.
8. Wang-Saegusa A, Cugat R, Ares O., Seijas R, Cusco X, Garcia-Balletbo M. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of ife. Arch Orthop Trauma Surg 2011; 131:311-317.
9. Andia I, Sanchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther 2012; 12:7-22.
10. Andia I, Sanchez M, Maffulli N. Platelet rich plasma therapies for sports muscle injuries: Any evidence behind clinical practice? Expert Opin Biol Ther 2011; 11:509-518.
11. Hamilton B, Knez W, Eirale C., Chalabi H. Platelet enriched plasma for acute muscle injury. Acta Orthop Belg 2010; 76:443-448.
12. Anitua E, Alkhraisat MH, Orive G. Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release 2012; 157:29-38.
13. Sanchez M, Anitua E, Orive G., Mujika I, Andia I. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med 2009; 39:345-354.
14. Anitua E, Prado R, Sanchez M., Orive G. Platelet-rich plasma: Preparation and formulation. Oper Tech Orthop 2012; 22:25-32.
15. McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 2012; 94:e1431-1438.
16. Schnabel LV, Mohammed HO, Miller B.J., McDermott WG, Jacobson MS, Santangelo KS, Fortier LA. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digi-torum superficialis tendons. J Orthop Res 2007; 25:230-240.
17. Scott A, Khan KM, Roberts C.R., Cook JL, Duronio V. What do we mean by the term "inflammation"? A contemporary basic science update for sports medicine. Br J Sports Med 2004; 38:372-380.
18. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011; 39:2135-2140.
19. de Jonge S, de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, Tol JL. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: A double-blind randomized placebo-controlled trial. Am J Sports Med 2011; 39:1623-1629.
20. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, Tol JL. Platelet-rich plasma injection for chronic Achilles tendinopathy: A randomized controlled trial. JAMA 2010; 303:144-149.
21. Horstmann WG, Slappendel R, van Hellemondt GG, Wymenga AW, Jack N, Everts PA. Autologous platelet gel in total knee arthroplasty: A prospective randomized study. Knee Surg Sports Traumatol Arthrosc 2011; 19:115-121.
22. Peerbooms JC, de Wolf GS, Colaris JW, Bruijn DJ, Verhaar JA. No positive effect of autologous platelet gel after total knee arthroplasty. Acta Orthop 2009; 80:557-562.
23. Dragoo JL, Braun HJ, Durham J.L., Ridley BA, Odegaard JI, Luong R, Arnoczky SP. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med 2012; 40:1274-1281.
24. Filardo G, Kon E, Pereira Ruiz MT, Vaccaro F, Guitaldi R, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: Single-versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc 2012; 20:2078-2087.
25. Kisiday JD, McIlwraith CW, Rodkey W.G., Frisbie DD, Steadman JR. Effects of platelet-rich plasma composition on anabolic and catabolic activities in equine cartilage and meniscal explants. Cartilage 2012; 3:245-254.
26. Bielecki T, Cieslik-Bielecka A, Åelawski M, Mikusek W. A side-effect induced by the combination of a demineralized freeze-dried bone allograft and leucocyte and platelet-rich plasma during treatment for large bone cysts: A 4-year follow-up clinical study. Transfus Apher Sci 2012; 47:133-138.
27. Bochsen L, Johansson PI, Kristensen A.T., Daugaard G., Ostrowski SR. The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis 2011; 22: 167-175.
28. Gersh KC, Nagaswami C, Weisel JW. Fibrin network structure and clot mechanical properties are altered by incorporation of erythro-cytes. Thromb Haemost 2009; 102:1169-1175.
29. Dohan Ehrenfest DM, Bielecki T, Jimbo R., Barbe G, Del Corso M, Inchingolo F, Sammartino G. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol 2012; 13:1145-1152.
30. Anitua E, Sanchez M, Nurden A.T., Zalduendo M., de la Fuente M, Orive G, Azofra J, Andia I. Autologous fibrin matrices: A potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A 2006; 77:285-293.
31. Perrin J, Morlon L, Vigneron C., Marchand-Arvier M. Influence of polymorphonuclear leukocytes on the plasma clot formation as evaluated by thromboelastometry (ROTEM). Thromb Res 2008; 121:647-652.
32. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16:137-161.
33. Helming L, Gordon S. The molecular basis of macrophage fusion. Immunobiology 2007; 212:785-793.
34. Grenier A, Chollet-Martin S, Crestani B., Delarche C, El Benna J, Boutten A, Andrieu V., Durand G, Gougerot-Pocidalo MA, Aubier M, Dehoux M. Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutro-phils. Blood 2002; 99:2997-3004.
35. Schuppan D, Schmid M, Somasundaram R., Ackermann R, Ruehl M, Nakamura T., Riecken EO. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 1998; 114: 139-152.
36. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. Faseb J 1997; 11:51-59.
37. Ohnishi T, Kakimoto K, Bandow K., Lowenstein CJ, Daikuhara Y, Matsuguchi T. Mature hepatocyte growth factor/scatter factor on the surface of human granulocytes is released by a mechanism involving activated factor Xa. J Immunol 2006; 176:6945-6953.
38. Kishuku M, Nishioka Y, Abe S., Kishi J, Ogino H, Aono Y., Azuma M, Kinoshita K, Batmunkh R, Makino H, Sone S. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their anti-angiogenic property. J Immunol 2009; 183:8176-8185.
39. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex B.H., Popel AS. A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010; 14:528-552.
40. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6:232-241.
41. Daheshia M, Yao JQ. The interleukin 1beta pathway in the patho-genesis of osteoarthritis. J Rheumatol 2008; 35:2306-2312.
42. Archambault J, Tsuzaki M, Herzog W., Banes AJ. Stretch and interleukin-1beta induce matrix metalloproteinases in rabbit tendon cells in vitro. J Orthop Res 2002; 20:36-39.
43. Tsuzaki M, Guyton G, Garrett W., Archambault JM, Herzog W, Almekinders L, Bynum D., Yang X, Banes AJ. IL-1 beta induces COX2, MMP-1, 23 and 213, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J Orthop Res 2003; 21:256-264.
44. Goldring MB. Osteoarthritis and cartilage: The role of cytokines. Curr Rheumatol Rep 2000; 2:459-465.
45. Center DM, Kornfeld H, Cruikshank WW. Interleukin-16. Int J Bio-chem Cell Biol 1997; 29:1231-1234.
46. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol 2000; 67:757-766.
47. Ludwiczek O, Kaser A, Koch R.O., Vogel W., Cruikshank WW, Tilg H. Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. Eur Cytokine Netw 2001; 12:478-486.
48. Conti P, Kempuraj D, Kandere K., Di Gioacchino M, Reale M, Barbacane R.C., Castellani ML, Mortari U, Boucher W, Letourneau R, Theoharides TC. Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc 2002; 23:103-108.
49. Blaschke S, Schulz H, Schwarz G., Blaschke V, Muller GA, ReussBorst M. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol 2001; 28:12-21.
50. Lard LR, Roep BO, Toes R.E., Huizinga TW. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 35-39.
51. Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T., Krol W, Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: An in vitro study. J Bone Joint Surg Br 2007; 89:417-420.
52. Moojen DJ, Everts PA, Schure R.M., Overdevest EP, van Zundert A, Knape JT, Castelein R.M., Creemers LB, Dhert WJ. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 2008; 26:404-410.
53. Anitua E, Alonso R, Girbau C., Aguirre JJ, Muruzabal F, Orive G. Antibacterial effect of plasma rich in growth factors (PRGF(R)-Endoret(R)) against Staphylococcus aureus and Staphylococcus epidermidis strains. Clin Exp Dermatol 2012; 37: 652-657.
54. Anitua E, Sanchez M, Prado R., Orive G. The type of platelet-rich plasma may influence the safety of the approach. Knee Surg Sports Traumatol Arthrosc 2012. doi:10.1007/s00167-012-2043-1.
55. Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet-rich plasma. Oper Tech Orthop 2012; 22:33-42.